Genzyme Targets InvaGen Over Kidney Treatment Generics
Genzyme Corp. sued InvaGen Pharmaceuticals Inc. on March 12 in New York, in an attempt to prevent the company from making and marketing generic versions of chronic kidney disease medications Renagel...To view the full article, register now.
Already a subscriber? Click here to view full article